Clinical Trials
13
Active:1
Completed:5
Trial Phases
5 Phases
Phase 1:7
Phase 2:1
Phase 3:3
+2 more phases
Drug Approvals
19
PHILIPPINES:19
Drug Approvals
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Phase 1
7 (53.8%)Phase 3
3 (23.1%)Not Applicable
1 (7.7%)Phase 2
1 (7.7%)Phase 4
1 (7.7%)A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State Study
Not Applicable
Not yet recruiting
- Conditions
- Type2 Diabetes Mellitus
- Interventions
- Drug: Comparator 1Drug: Comparator 2Drug: Test Drug
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- AJU Pharm Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT07044765
- Locations
- 🇰🇷
Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, Gyeonggi-do, Korea, Republic of
A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults
Phase 1
Not yet recruiting
- Conditions
- Type2 Diabetes Mellitus
- Interventions
- Drug: Comparator 1Drug: Comparator 2Drug: Test Drug
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- AJU Pharm Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT07034781
- Locations
- 🇰🇷
Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, Gyeonggi-do, Korea, Republic of
To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C714 and C714R in Healthy Adults
Phase 1
Active, not recruiting
- Conditions
- Dyslipidemia
- Interventions
- Drug: Test DrugDrug: Reference Drug
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- AJU Pharm Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06933459
- Locations
- 🇰🇷
H+ Yangji Hospital, Seoul, Republic of South Korea, Seoul, Korea, Republic of
To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C711 in Healthy Adults
Phase 1
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- Drug: Test DrugDrug: Reference Drug
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- AJU Pharm Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06931327
- Locations
- 🇰🇷
Bumin Hospital, Seoul, Republic of South Korea, Seoul, Korea, Republic of
Efficacy and Safety of AJU-C52 in Essential Hypertension Patients
Phase 3
Recruiting
- Conditions
- Essential Hypertension
- Interventions
- Drug: AJU-C52L, AJU-C52Drug: C52R1L, C52R1M
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- AJU Pharm Co., Ltd.
- Target Recruit Count
- 190
- Registration Number
- NCT06416865
- Locations
- 🇰🇷
AJU Pharm Co., Ltd., Seoul, Korea, Republic of
- Prev
- 1
- 2
- 3
- Next
News
No news found